Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 2
1980 1
1982 1
1986 1
1988 3
1989 3
1990 2
1991 3
1992 2
1993 1
1995 1
1997 2
1998 1
1999 1
2002 1
2004 1
2005 2
2007 2
2008 1
2009 1
2010 5
2011 5
2012 2
2013 3
2014 3
2015 3
2016 3
2017 4
2018 1
2019 6
2020 3
2021 2
Text availability
Article attribute
Article type
Publication date

Search Results

64 results
Results by year
Filters applied: . Clear all
Page 1
FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy.
Diaz Osterman CJ, Ozmadenci D, Kleinschmidt EG, Taylor KN, Barrie AM, Jiang S, Bean LM, Sulzmaier FJ, Jean C, Tancioni I, Anderson K, Uryu S, Cordasco EA, Li J, Chen XL, Fu G, Ojalill M, Rappu P, Heino J, Mark AM, Xu G, Fisch KM, Kolev VN, Weaver DT, Pachter JA, Győrffy B, McHale MT, Connolly DC, Molinolo A, Stupack DG, Schlaepfer DD. Diaz Osterman CJ, et al. Among authors: pachter ja. Elife. 2019 Sep 3;8:e47327. doi: 10.7554/eLife.47327. Elife. 2019. PMID: 31478830 Free PMC article.
A Platform of Synthetic Lethal Gene Interaction Networks Reveals that the GNAQ Uveal Melanoma Oncogene Controls the Hippo Pathway through FAK.
Feng X, Arang N, Rigiracciolo DC, Lee JS, Yeerna H, Wang Z, Lubrano S, Kishore A, Pachter JA, König GM, Maggiolini M, Kostenis E, Schlaepfer DD, Tamayo P, Chen Q, Ruppin E, Gutkind JS. Feng X, et al. Among authors: pachter ja. Cancer Cell. 2019 Mar 18;35(3):457-472.e5. doi: 10.1016/j.ccell.2019.01.009. Epub 2019 Feb 14. Cancer Cell. 2019. PMID: 30773340 Free PMC article.
Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells.
Zhou L, Huntington K, Zhang S, Carlsen L, So EY, Parker C, Sahin I, Safran H, Kamle S, Lee CM, Lee CG, Elias JA, Campbell KS, Naik MT, Atwood WJ, Youssef E, Pachter JA, Navaraj A, Seyhan AA, Liang O, El-Deiry WS. Zhou L, et al. Among authors: pachter ja. bioRxiv. 2020 Aug 3:2020.08.02.230839. doi: 10.1101/2020.08.02.230839. Preprint. bioRxiv. 2020. PMID: 32793908 Free PMC article.
PYK2/FAK inhibitors reverse hypoxia-induced drug resistance in multiple myeloma.
Muz B, Buggio M, Azab F, de la Puente P, Fiala M, Padval MV, Weaver DT, Pachter JA, Vij R, Azab AK. Muz B, et al. Among authors: pachter ja. Haematologica. 2019 Jul;104(7):e310-e313. doi: 10.3324/haematol.2018.194688. Epub 2019 Jan 17. Haematologica. 2019. PMID: 30655367 Free PMC article. No abstract available.
Synergism of FAK and tyrosine kinase inhibition in Ph+ B-ALL.
Churchman ML, Evans K, Richmond J, Robbins A, Jones L, Shapiro IM, Pachter JA, Weaver DT, Houghton PJ, Smith MA, Lock RB, Mullighan CG. Churchman ML, et al. Among authors: pachter ja. JCI Insight. 2016;1(4):e86082. doi: 10.1172/jci.insight.86082. Epub 2016 Apr 7. JCI Insight. 2016. PMID: 27123491 Free PMC article.
Inhibition of FAK kinase activity preferentially targets cancer stem cells.
Kolev VN, Tam WF, Wright QG, McDermott SP, Vidal CM, Shapiro IM, Xu Q, Wicha MS, Pachter JA, Weaver DT. Kolev VN, et al. Among authors: pachter ja. Oncotarget. 2017 Jun 16;8(31):51733-51747. doi: 10.18632/oncotarget.18517. eCollection 2017 Aug 1. Oncotarget. 2017. PMID: 28881682 Free PMC article.
Focal Adhesion Kinase as a Potential Target in AML and MDS.
Carter BZ, Mak PY, Wang X, Yang H, Garcia-Manero G, Mak DH, Mu H, Ruvolo VR, Qiu Y, Coombes K, Zhang N, Ragon B, Weaver DT, Pachter JA, Kornblau S, Andreeff M. Carter BZ, et al. Among authors: pachter ja. Mol Cancer Ther. 2017 Jun;16(6):1133-1144. doi: 10.1158/1535-7163.MCT-16-0719. Epub 2017 Mar 7. Mol Cancer Ther. 2017. PMID: 28270436 Free PMC article.
64 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page